MedTrace Logo

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

NCT04739215 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-02-04

No results posted yet for this study

Summary

The main aim of this study is to identify the underlying mechanisms of Sodium-glucose co-transporter-2 (SGLT2) inhibitors which are associated to better outcomes in patients with Diabetes mellitus type 2 and Heart Failure with preserved Ejection Fraction.

Conditions

Interventions

DRUG

Dapagliflozin 10 MG [Farxiga]

Dapagliflozin 10 mg / day oral

DRUG

Placebo

One Placebo capsule daily oral

Sponsors & Collaborators

  • University of Navarra

    collaborator OTHER

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Fundación para la Investigación Biomédica del Hospital Gregorio Maranon

    collaborator OTHER

  • Hospital General Universitario Gregorio Marañon

    lead OTHER

Principal Investigators

  • Javier Bermejo Thomas, MD, PhD · Hospital General Universitario Gregorio Marañón

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04739215 on ClinicalTrials.gov